Sledge Jr. GW, et al. MONARCH 2: Overall survival of abemaciclib plus fulvestrant in patients with HR+, HER2- advanced breast cancer. LBA6_PR. ESMO 2019. 28 sep.-1 okt. 2019, Barcelona, Spanje.
Congressen IGCA en ESDE: beide geslaagd, en ook verbinding
jul 2025 | Maag-darm-leveroncologie